News

2009-12-03 Pharmacy and biotech unite for the fight with cancer

Pharmaceutical company Adamed together with biotech start-up BioCentrum started a project on developing new, innovative anticancer drug. Decision was made on the 25th November 2009.

First phase of the project will concentrate on the identification and characterization of structurally new compounds – inhibitors of one of the oncogenic mechanisms. Clinical studies will follow in the second phase of the project, and are planned to start in 2013. The drug will be potentially applied to about 3 million patients in the world.

According to the words of Malgorzata Korpusik, head of Adamed R&D department, the pharmaceutical will enable target therapy, since it will be directed straightly to the site of tumour and will eradicate solely the cells transformed with the disease. Healthy tissue should be left untouched.

Jagiellonian Department of Biochemistry, Biophysics and Biotechnology together with a company Selvita, a strategic BioCentrum partner, are also supporting the project.

Adamed – pharmaceutical company introducing new generation medicaments of different therapeutic applications (cardiology, psychiatry, pulmonology, urology, gynecology, oncology) to the Polish market. < br> Company was established in 1986, and today is an owner of two large drug manufacturing plants in Poland. The mission is searching for new therapies for civilization diseases.
Adamed has invested over 150mlnPLN in R&D within the last 5 years working out over 20 patents for own drugs.

BioCentrum – biotech company, which provides services in preclinical research for drug development and in the pharmaceutical, biotechnological and chemical sectors. It also is a producer of biologically active proteins, such as enzymes, inhibitors, monoclonal antibodies.
The company operates in the market since 2004.

Press information

Magdalena Zychlinska-Jackiewicz